Abstract
Introduction

33
Marbofloxacin is a synthetic fluoroquinolone, developed for veterinary use only 34 (47). Belonging to the third generation of quinolones it has a broad spectrum of 35 activity (58), and a bactericidal concentration-dependent killing is observed against 36 many Gram-negative bacteria (12, 49, 51, 52). The pharmacokinetic properties of 37 marbofloxacin have been studied in several mammalian species, and some advantages 38 over other fluoroquinolones, such as a longer elimination half-life were described (2, Marbofloxacin solutions at twice the required final concentration of 128 µg/ml 122 were added either to MHB (according to NCCLS, 2000, 41) or to blood serum 123 obtained from control animals. Serial dilutions from this solution were prepared in 124 broth and in serum with concentration ranging between 64 µg/ml and 0.0156 µg/ml 125 and were inoculated with approximately 5x10 5 CFU/ml E. coli O78/K80. Tubes were 126 incubated at 35°C for 18 h and then shaken to mix the contents.
and Bactericidal Activity serum were defined as the concentration at which a 99.9% 132 reduction in the bacterial counts was achieved. 133
134
Antimicrobial activity in the serum of animals treated with marbofloxacin 135
Eight to ten colonies from overnight growth of E. coli in TSA (as mentioned 136 above) were used to inoculate 9 ml of MHB, and the colonies were allowed to grow 137 overnight at 35°C. 138
To 0.5 ml serum from treated animals 5 µl of the stationary phase of bacterial 139 cultures was added, to give a final concentration of approximately 3x10 7 CFU/ml. 140
To determine the number of CFU, serial dilutions were prepared with sterile 141 saline (ranging from 10 -2 to 10 -6 CFU/ml) and incubated for 3, 6, and 24 h. Thereafter 142 an aliquot of 20 µl was plotted on TSA plates and CFUs were counted after 16 h 143 incubations. The limit of detection was 10 CFU/ml. 144
145
Determination of marbofloxacin serum concentrations 146
HPLC method
147
The serum concentrations of marbofloxacin were determined by HPLC 148 according to the method of analysis as described by Garcia et al. (20) . Standard 149 solutions were prepared in serum obtained from untreated turkeys at concentrations of 150 2.5, 1.0, 0.5, 0.2, 0.1, 0.05, 0.025, 0.02 (LOQ) and 0.01 (LOD) µg marbofloxacin per 151 ml. The value of r for the standard curve was 0.998 and the linearity was confirmed 152 by the test for lack of fit (P=0.653). The intra-assay and the inter-assay coefficients of 153 variation (CV) for marbofloxacin were calculated to be 9.18 and 5.87, respectively. were prepared in serum obtained from untreated animals. The value of r for the 160 standard curve was 0.993 and the linearity was confirmed by the test for lack of fit 161 (P=0.749). The intra-assay CV was 9.09 and the inter-assay CV was 10.60. The limit 162 of quantification in serum samples was 0.04 µg/ml. 163
A C C E P T E D
164
Pharmacokinetic analysis 165
Pharmacokinetic analysis of the data was performed using non-compartmental 166 analysis based on statistical moments theory (21) (WinNonlin 4.0. Antibacterial efficacy was quantified from the sigmoid E max equation (Equation 217 2) by determining Concentration 24h /InhibitoryActivity serum required for a bacteriostatic 218 effect (no change in bacterial count after 24 h of incubation), a 50% reduction in the 219 bacterial count, a bactericidal effect (a 99.9% decrease in the bacterial count), and for 220 the bacterial elimination (the lowest Concentration 24h /InhibitoryActivity serum that 221 produced a reduction in bacterial counts to 10 CFU/ml) in serum (1) . 222
Statistical analyses
224
The pharmacokinetic parameters of marbofloxacin were presented as mean + 225 standard deviation. They were computed with the Statistica 6. 
